Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content

Specific PHGKB|Pharmacogenomics PHGKB|PHGKB

Last Posted: Jun 17, 2021
spot light Spotlight

Genetic-guided pharmacotherapy for venous thromboembolism: a systematic and critical review of economic evaluations
KK Lim et al, Pharmacogenomics Journal, June 15, 2021

The ten eligible studies, all model-based, examined heterogeneous interventions and comparators. Findings varied widely; testing was cost-saving in two base-cases, cost-effective in four, not cost-effective in three, dominated in one. Of 22 model variables that changed decisions about cost-effectiveness, effectiveness/relative effectiveness of the intervention was the most frequent, albeit of poor quality.

Determining the potential clinical value of panel-based pharmacogenetic testing in patients with chronic pain or gastroesophageal reflux disease
AL Elchynsky et al, The PGx journal, June 3, 2021

We aimed to determine the potential value of panel-based pharmacogenetic (PGx) testing in patients with chronic pain or gastroesophageal reflux disease (GERD) who underwent single-gene PGx testing to guide opioid or proton pump inhibitor (PPI) therapy, respectively. Of 448 patients included (chronic pain, n?=?337; GERD, n?=?111), mean age was 57 years, 68% were female, and 73% were white. Excluding opiates for the pain cohort and PPIs for the GERD cohort, 76.6% of patients with pain and 71.2% with GERD were prescribed at least one additional medication with a high level of PGx evidence, most commonly ondansetron or selective serotonin reuptake inhibitors.

Clinical Implications of Pharmacogenomic Testing in the Real World—Insights From a Pediatric Program
CC Coffinier, JAMA Network Open, May 26, 2021

One challenge identified in general PGx implementation, which may be magnified in the pediatric setting, is that the full benefit of acquiring PGx test results may not be apparent until later in life. Integrating PGx information into electronic health records and ensuring its high visibility using reminders and alerts are fundamental steps to facilitate future use; otherwise, even a simple change in clinicians within the same health care system is likely to result in the loss of information.

Assessment of the Implementation of Pharmacogenomic Testing in a Pediatric Tertiary Care Setting
I Cohn et al, JAMA Network Open, May 26, 2021

In this cohort study of 172 pediatric patients, pharmacogenomic testing of 6 pharmacogenes (CYP2D6, CYP2C9, CYP2C19, CYP3A5, TPMT, and VKORC1) provided results that warranted deviation from standard treatment regimens in approximately 40% of patients in the point-of-care evaluation of targeted drugs and 80% of patients in the preemptive evaluation of a broader range of drugs for potential therapy.

news Latest News and Publications
Genotyping NUDT15*3 rs1166855232 reveals higher frequency of potential adverse effects of thiopurines in Natives and Mestizos from Mexico. External Web Site Icon
Texis Tomas et al. Pharmacological reports : PR 2021
Moving Pharmacogenetics into Practice: It's All About the Evidence! External Web Site Icon
Luzum Jasmine A et al. Clinical pharmacology and therapeutics 2021
PharmVar: A Global Resource and Repository for Pharmacogene Variation. External Web Site Icon
Gaedigk Andrea et al. Clinical pharmacology and therapeutics 2021
Recommendations for Clinical CYP2D6 Genotyping Allele Selection: A Joint Consensus Recommendation of the Association for Molecular Pathology, College of American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, and European Society for Pharmacogenomics and Personalized Therapy. External Web Site Icon
Pratt Victoria M et al. The Journal of molecular diagnostics : JMD 2021
A Pharmacogenetic Study of CYP2C19 in Acute Coronary Syndrome Patients of Colombian Origin Reveals New Polymorphisms Potentially Related to Clopidogrel Therapy. External Web Site Icon
Angulo-Aguado Mariana et al. Journal of personalized medicine 2021 11(5)
Efficacy of PCSK9 inhibitors in the treatment of heterozygous familial hypercholesterolemia: A clinical practice experience. External Web Site Icon
Alonso Rodrigo et al. Journal of clinical lipidology 2021
High-throughput framework for genetic analyses of adverse drug reactions using electronic health records. External Web Site Icon
Zheng Neil S et al. PLoS genetics 2021 17(6) e1009593
Implementing Pharmacogenomics Testing: Single Center Experience at Arkansas Children's Hospital. External Web Site Icon
Gill Pritmohinder S et al. Journal of personalized medicine 2021 11(5)
Multi-Institutional Implementation of Clinical Decision Support for APOL1, NAT2, and YEATS4 Genotyping in Antihypertensive Management. External Web Site Icon
Schneider Thomas M et al. Journal of personalized medicine 2021 11(6)
Assessment of the Implementation of Pharmacogenomic Testing in a Pediatric Tertiary Care Setting. External Web Site Icon
Cohn Iris et al. JAMA network open 2021 4(5) e2110446


Disclaimer: Articles listed in the Public Health Knowledge Base are selected by the CDC Office of Public Health Genomics to provide current awareness of the literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the update, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.